These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 8952563)

  • 1. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
    Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
    Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
    Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
    Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas.
    Jeffers MD; Richmond JA; Macaulay EM
    Mod Pathol; 1995 Sep; 8(7):701-4. PubMed ID: 8539225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
    Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
    Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma.
    Nordal RR; Kristensen GB; Kaern J; Stenwig AE; Pettersen EO; Tropé CG
    Gynecol Oncol; 1996 Aug; 62(2):254-9. PubMed ID: 8751558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.
    Nordal RR; Kristensen GB; Kaern J; Stenwig AE; Pettersen EO; Tropé CG
    Acta Oncol; 1995; 34(6):797-802. PubMed ID: 7576748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Belda MALF; Averous G; Leroux A; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
    Gynecol Oncol; 2022 Nov; 167(2):373-389. PubMed ID: 36114030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial stromal sarcoma of uterus.
    Xue WC; Cheung AN
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):719-32. PubMed ID: 21820965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant mesenchymal tumors of the uterus - time to advocate a genetic classification.
    Rommel B; Holzmann C; Bullerdiek J
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1155-1166. PubMed ID: 27602604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine sarcomas.
    Mbatani N; Olawaiye AB; Prat J
    Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():51-58. PubMed ID: 30306577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey.
    Durnali A; Tokluoğlu S; Özdemir N; Inanç M; Alkiş N; Zengin N; Sönmez ÖU; Küçüköner M;
    Asian Pac J Cancer Prev; 2012; 13(5):1935-41. PubMed ID: 22901150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deoxyribonucleic acid analysis by flow cytometry of uterine leiomyosarcomas and smooth muscle tumors of uncertain malignant potential.
    Peters WA; Howard DR; Andersen WA; Figge DC
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 1):1646-53; discussion 1653-4. PubMed ID: 1615971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine sarcomas: a review.
    D'Angelo E; Prat J
    Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myxoid Mesenchymal Tumors of the Uterus: An Update on Classification, Definitions, and Differential Diagnosis.
    Busca A; Parra-Herran C
    Adv Anat Pathol; 2017 Nov; 24(6):354-361. PubMed ID: 28787279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors.
    Chou FF; Eng HL; Sheen-Chen SM
    Surgery; 1996 Feb; 119(2):171-7. PubMed ID: 8571202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype.
    Oliva E; Clement PB; Young RH
    Adv Anat Pathol; 2000 Sep; 7(5):257-81. PubMed ID: 10976906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
    Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
    Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.